US EditionPublished • loading... • Updated
Cogent Biosciences, Inc. (COGT) Stock Analysis: Potential 38% Upside As Analysts Show Strong Buy Interest
Summary by DirectorsTalk Interviews
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Cogent Biosciences, Inc. (COGT) Stock Analysis: Potential 38% Upside As Analysts Show Strong Buy Interest
Cogent Biosciences, Inc. (NASDAQ: COGT) is capturing the attention of investors with its significant potential upside and robust analyst support. As a biotechnology company focused on precision therapies for genetically defined diseases, Cogent is leveraging cutting-edge science to tackle challenging medical conditions. Based in Waltham, Massachusetts, Cogent’s innovative portfolio includes promising candidates like bezuclastinib, currently in P…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
